[Because fee settlement means are not widely known. Deficits in hepatitis C therapy].
D000998:Antiviral Agents / Q000191:economics / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005251:Fees, Medical / Q000331:legislation & jurisprudence*; D005858:Germany; D006526:Hepatitis C / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D019458:Insurance Coverage / Q000191:economics*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000191:economics / Q000627:therapeutic use; D009313:National Health Programs / Q000191:economics*; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000191:economics / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a